Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.
about
Muscle-invasive urothelial bladder cancer: an update on systemic therapyShedding new light on neurodegenerative diseases through the mammalian target of rapamycinClinical Translation of Nanomedicine.Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trialPeriostin suppresses in vivo invasiveness via PDK1/Akt/mTOR signaling pathway in a mouse orthotopic model of bladder cancerA systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.Cell-free urinary microRNA-99a and microRNA-125b are diagnostic markers for the non-invasive screening of bladder cancerMammalian target of rapamycin complex 2 (mTORC2) is a critical determinant of bladder cancer invasionHistopathological assessment of inflammation and expression of inflammatory markers in patients with ketamine-induced cystitis.Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies.Personalized therapy for urothelial cancer: review of the clinical evidence.Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage disease.GOLPH3 is a potential therapeutic target and a prognostic indicator of poor survival in bladder cancer treated by cystectomy.The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo.Transforming Growth Factor-β Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2-Dependent Bladder Cancer Cell Migration and InvasionThe effect of gartanin, a naturally occurring xanthone in mangosteen juice, on the mTOR pathway, autophagy, apoptosis, and the growth of human urinary bladder cancer cell linesAMPKα Is Suppressed in Bladder Cancer through Macrophage-Mediated Mechanisms.Targeted inhibition of mTOR signaling improves sensitivity of esophageal squamous cell carcinoma cells to cisplatin.Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway.Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.Novel molecular targets for the therapy of urothelial carcinoma.New treatments for bladder cancer: when will we make progress?Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer.mTOR inhibitors in urinary bladder cancer.Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signalling.The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivoAutophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells.Phospho-mTOR in non-tumour and tumour bladder urothelium: Pattern of expression and impact on urothelial bladder cancer patients.Suppression of HSP27 increases the anti‑tumor effects of quercetin in human leukemia U937 cellsMetformin induces degradation of mTOR protein in breast cancer cells.Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors.Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
P2860
Q26775780-16B8EC06-E12C-48D1-BA49-C90CCE222407Q27015640-E6519C28-F70B-479C-961E-6A76FAE1102DQ30355939-D8D1FC53-7DA2-44AC-ADEF-C8C26F9415D5Q33410691-E690735A-2D05-41C7-88C9-0B0024CCC491Q33751028-9355355D-F815-458C-8FA5-B4A3607204D9Q33886553-DDB2951B-0501-4E0D-A6E2-4F5945816851Q33889872-D39C05A2-62D6-4713-8950-8722DB8848D9Q35060424-42CCB33B-DE67-4A9B-AD8B-638533B29387Q35110940-178556F1-3345-4261-8AD4-CBBF0567548DQ35157985-EE50078A-E621-4615-B5CD-D2225C7DB70CQ36027204-0D913A86-6804-466D-A8AD-7849968FD59BQ36061127-C0BD2386-306F-4887-A75D-0EB2994514E8Q36062762-C36A5263-A7C0-43D1-966A-7E685927A0ADQ36087194-1F150F36-1749-4917-A8D8-19CD1FF45CC3Q36544805-3428C2C9-539D-4558-B103-15529D899A92Q36765779-A41A5C77-7FF8-4221-BEB1-EF9BD9B04D16Q36820882-FBEE5E10-E9B6-4845-940F-6015D4739DAFQ36885716-F7F019B0-E093-47CB-99D7-22479F0448EEQ36899375-D0FC10BA-7C2B-44EF-9677-2B77C1F87EEEQ37482647-E40D655D-B6E9-44F7-9D9D-7571A8A59728Q37730668-9A8DD550-8637-4AE9-9BD0-A7EFDA04F653Q37775890-2D81B6F7-C40F-4CAF-B080-132436F9F2BAQ37871915-FD20D372-EDB2-4784-AF55-43F21A02D455Q38003195-76514783-8E19-47B4-BB57-D6E5D21CBE34Q38177753-40A26D72-29BB-443E-A254-2E0470721DC1Q38312045-AB53C9E1-D054-4B4F-88DA-4F823B2DA355Q38735342-69B065AB-27B9-44C1-9246-4FDDEDE79F7AQ38737064-32CCFB35-A6D5-4492-9BD0-1C38DA3F0813Q38807880-021C3336-E230-466B-9464-A46355FE73A7Q39042097-20640274-3E69-461D-A650-BCD2DF3EA95CQ40510800-83458072-21BF-4EF7-AA5E-DC7F65620FD4Q41913207-4B4B1055-7292-408D-B368-352A4670E46DQ42068149-B34E1AD8-5375-4747-AE99-8E6073E7E915Q42364561-E1C09C4B-1588-442F-883B-DF1D0AE7F00DQ47140976-A60E551A-5454-4AAC-A821-20E7E7F58AF9Q48839946-12F25080-9CDB-4581-8649-06DE43C34377Q54285690-69532F83-ACDD-4700-BF71-391EF6BEFE59
P2860
Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Mammalian target of rapamycin ...... rowth in urothelial carcinoma.
@ast
Mammalian target of rapamycin ...... rowth in urothelial carcinoma.
@en
type
label
Mammalian target of rapamycin ...... rowth in urothelial carcinoma.
@ast
Mammalian target of rapamycin ...... rowth in urothelial carcinoma.
@en
prefLabel
Mammalian target of rapamycin ...... rowth in urothelial carcinoma.
@ast
Mammalian target of rapamycin ...... rowth in urothelial carcinoma.
@en
P2093
P2860
P1476
Mammalian target of rapamycin ...... rowth in urothelial carcinoma.
@en
P2093
Angelo De Marzo
Christina B Ching
Dan Theodorescu
Donna E Hansel
Eric D Hsi
Eric Platt
Jessica L Hicks
Jyoti Harwalker
Mohammed Orloff
Roxanne E Steinle
P2860
P304
P356
10.2353/AJPATH.2010.090872
P407
P50
P577
2010-04-15T00:00:00Z